Teva's Shared Solutions® for AUSTEDO® HD Chorea Patients
ADDING MULTIMEDIA Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults | Business
Teva COPAXONE 2019 Pharmaceutical Manufacturer Sharps Disposal Plan
teva_1.jpg
COPAXONE Co‐Pay Solutions®: Co‐Pay Card & Financial Assistance
Teva Launches 'It's Not OK - It's TD' National Television Advertising Campaign to Increase Awareness of Tardive Dyskinesia and AUSTEDO® (deutetrabenazine) tablets
Teva Pharmaceuticals and IBM Partner to Build Global e-Health Solutions on the IBM Watson Health Cloud
Travel with Copaxone: Top Ten Tips! - Our Carpe Diem
Get to Know Teva's Shared Solutions® | AUSTEDO® (deutetrabenazine) tablets
Resources | Teva CORE
CINQAIR® (reslizumab) Injection - Savings and Support
Drug Pricing Investigation
Shared Solutions® Support Program
Savings Offer | AJOVY® (fremanezumab-vfrm) injection
Shared Solutions® - Become a member
SHARED SOLUTIONS PHARMACY Trademark of TEVA NEUROSCIENCE, INC. Serial Number: 86567663 :: Trademarkia Trademarks
Teva Shared Solutions® Digital Services for COPAXONE®
U.S. v. Teva Pharmaceuticals USA, Inc., and Teva Neuroscience, Inc. - Complaint
Tardive Dyskinesia (TD) Resources for You and Your Patients | AUSTEDO® (deutetrabenazine) tablets
Shared Solutions® - Services
Discover Financial Assistance & Adherence Support Today!
COPAXONE® (glatiramer acetate injection) - Teva's Shared Solutions® is here every step of the way. Learn more: copaxone.com/shared-solutions. | Facebook
